Shares of ProMetic Life Sciences Inc. (TSE:PLI) have been given a consensus recommendation of “Buy” by the eight analysts that are presently covering the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is C$4.86.

Several analysts recently weighed in on the company. Royal Bank Of Canada restated an “outperform” rating on shares of ProMetic Life Sciences in a research note on Thursday. Scotiabank restated an “outperform” rating and set a C$5.00 target price on shares of ProMetic Life Sciences in a research note on Wednesday, August 10th. CIBC decreased their target price on ProMetic Life Sciences from C$5.00 to C$4.85 in a research note on Thursday, August 25th. Finally, TD Securities restated a “speculative buy” rating and set a C$4.50 target price on shares of ProMetic Life Sciences in a research note on Wednesday, September 28th.

Shares of ProMetic Life Sciences (TSE:PLI) traded down 2.84% on Thursday, reaching $3.08. 933,368 shares of the company’s stock traded hands. ProMetic Life Sciences has a 12-month low of $1.67 and a 12-month high of $3.62. The company’s market cap is $1.86 billion. The stock has a 50-day moving average price of $2.92 and a 200-day moving average price of $3.01.

ProMetic Life Sciences Company Profile

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.